Comparing Therapeutic Efficacy and Safety of Epoetin Beta and Epoetin Alfa in the Treatment of Anemia in End-Stage Renal Disease Hemodialysis Patients
Conclusion: CinnaPoietin ® was proved to be non-inferior to Eprex® in the treatment of anemia in ESRD hemodialysis patients. The trial was registered in Clinicaltrials.gov (NCT03408639).Am J Nephrol 2018;48:251 –259 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - October 5, 2018 Category: Neurology Source Type: research
Comparing Therapeutic Efficacy and Safety of Epoetin Beta and Epoetin Alfa in the Treatment of Anemia in End-Stage Renal Disease Hemodialysis Patients.
CONCLUSION: CinnaPoietin® was proved to be non-inferior to Eprex® in the treatment of anemia in ESRD hemodialysis patients. The trial was registered in Clinicaltrials.gov (NCT03408639).
PMID: 30253403 [PubMed - as supplied by publisher] (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - September 25, 2018 Category: Urology & Nephrology Authors: Azmandian J, Abbasi MR, Pourfarziani V, Nasiri AA, Ossareh S, Ezzatzadegan Jahromi S, Sanadgol H, Amini S, Shahvaroughi Farahani A Tags: Am J Nephrol Source Type: research
Switching from Epoetin Alfa (Epogen ®) to Epoetin Alfa-Epbx (Retacrit < sup > TM < /sup > ) Using a Specified Dosing Algorithm: A Randomized, Non-Inferiority Study in Adults on Hemodialysis
Conclusions: Switching to RetacritTM was non-inferior to continuing Epogen® in maintaining hemoglobin levels in patients receiving hemodialysis, when both ESAs were dosed using a specified algorithm (ClinicalTrials.gov, NCT02504294).Am J Nephrol 2018;48:214 –224 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - September 7, 2018 Category: Neurology Source Type: research
Switching from Epoetin Alfa (Epogen ®) to Epoetin Alfa-Epbx (RetacritTM) Using a Specified Dosing Algorithm: A Randomized, Non-Inferiority Study in Adults on Hemodialysis.
CONCLUSIONS: Switching to RetacritTM was non-inferior to continuing -Epogen® in maintaining hemoglobin levels in patients receiving hemodialysis, when both ESAs were dosed using a specified algorithm (ClinicalTrials.gov, NCT02504294).
PMID: 30196301 [PubMed - as supplied by publisher] (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - September 7, 2018 Category: Urology & Nephrology Authors: Thadhani R, Guilatco R, Hymes J, Maddux FW, Ahuja A Tags: Am J Nephrol Source Type: research
Magnetic nanoparticles and polydopamine amplified FP aptasensor for the highly sensitive detection of rHuEPO- α.
Magnetic nanoparticles and polydopamine amplified FP aptasensor for the highly sensitive detection of rHuEPO-α.
Talanta. 2018 Nov 01;189:143-149
Authors: Chen Z, Li H, Zhao Y, Xu M, Xu D
Abstract
In this paper, an amplified fluorescence polarization (FP) aptasensor based on magnetic nanoparticles @polydopamine (MNP@PDA) was innovatively developed for sensitive detection of recombinant human erythropoietin-alpha(rHuEPO-α). The amplified FP signal was due to the large mass of protein and MNP@PDA. And this assay can be utilized for target separation or recycling based on the magnet...
Source: Talanta - August 9, 2018 Category: Chemistry Authors: Chen Z, Li H, Zhao Y, Xu M, Xu D Tags: Talanta Source Type: research
Comparative Safety of Originator and Biosimilar Epoetin Alfa Drugs: An Observational Prospective Multicenter Study
ConclusionThis study confirms the comparable safety profiles of originator and biosimilar epoetin alfa drugs when used in patients receiving dialysis. (Source: BioDrugs)
Source: BioDrugs - August 1, 2018 Category: Drugs & Pharmacology Source Type: research
Pharmaceutical Approval Update.
Authors: Choy M
Abstract
Fostamatinib (Tavalisse) for thrombocytopenia in adults with chronic immune thrombocytopenia; coagulation factor Xa (recombinant), inactivated-zhzo (Andexxa) for the reversal of anticoagulation; epoetin alfa-epbx (Retacrit), a biosimilar for the treatment of anemia.
PMID: 30013295 [PubMed] (Source: P and T)
Source: P and T - July 18, 2018 Category: Drugs & Pharmacology Tags: P T Source Type: research
Patterns of Erythropoiesis-Stimulating Agent Use in European Hemodialysis Patients: The Dialysis Outcomes and Practice Patterns Study
Conclusion: A variety of short- and long-acting ESAs are commonly used in European HD facilities to maintain hemoglobin at remarkably similar levels with each ESA type. The availability of numerous ESA options for managing anemia has allowed European providers to optimize anemia management according to the particular circumstances of each patient.Nephron (Source: Nephron)
Source: Nephron - June 26, 2018 Category: Urology & Nephrology Source Type: research
Intravenous Epoetin Alfa-epbx versus Epoetin Alfa for Treatment of Anemia in End-Stage Kidney Disease.
CONCLUSIONS: This 24-week, comparative, clinical trial in patients on hemodialysis with ESKD and anemia demonstrated there is no clinically meaningful difference in efficacy or safety between epoetin alfa-epbx and epoetin alfa.
PMID: 29921734 [PubMed - as supplied by publisher] (Source: Clinical Journal of the American Society of Nephrology : CJASN)
Source: Clinical Journal of the American Society of Nephrology : CJASN - June 19, 2018 Category: Urology & Nephrology Authors: Fishbane S, Singh B, Kumbhat S, Wisemandle WA, Martin NE Tags: Clin J Am Soc Nephrol Source Type: research
Biosimilar Approved for Anemia
The first biosimilar to epoetin alfa for patients with anemia from chronic kidney disease, chemotherapy, or zidovudine treatment for HIV infection has receivedFDA approval. (Source: JAMA)
Source: JAMA - June 19, 2018 Category: General Medicine Source Type: research
Epoetin alfa resistance in hemodialysis patients with chronic kidney disease: a longitudinal study.
This study aimed to investigate the factors associated with resistance to recombinant human erythropoietin therapy with epoetin alfa (αEPO). We performed a prospective, longitudinal study of hemodialysis patients receiving treatment with αEPO at our reference hospital from July 2015 to June 2016. Clinical data was collected, and the response to αEPO treatment was evaluated using the erythropoietin resistance index (ERI). The ERI was defined as the weekly weight-adjusted αEPO dose (U/kg per week)/hemoglobin level (g/dL). A longitudinal linear regression model was fitted with random effects to verify the relationships be...
Source: Brazilian Journal of Medical and Biological Research - May 10, 2018 Category: Research Tags: Braz J Med Biol Res Source Type: research
Priapism and hemodialysis: Case report and literature review
.
CONCLUSION: Priapism is a rarely reported complication of dialysis in adult patients and has not been described in pediatric dialysis patients. The etiology remains unclear but is hypothesized to be multifactorial including heparin-associated effects and epoetin administration. In our patients, commonality between the two included presumed high androgen levels (given age) and borderline to high hemoglobin levels in patients receiving epoetin alfa. This in combination with prior studies highlights the possible role epoetin administration may play. The role of heparin remains a possibility but is unclear. Further studies are...
Source: Clinical Nephrology - March 26, 2018 Category: Urology & Nephrology Authors: Shih WV, Wong C Tags: Clin Nephrol Source Type: research
Erythropoietin Does Not Alter Serum Profiles of Neuronal and Axonal Biomarkers After Traumatic Brain Injury: Findings From the Australian EPO-TBI Clinical Trial
Conclusions:
Serum ubiquitin carboxy-terminal hydrolase L1 and phosphorylated neurofilament heavy-chain increase after traumatic brain injury reflecting early neuronal and progressive axonal injury. Consistent with lack of improved outcome in traumatic brain injury patients treated with erythropoietin, biomarker concentrations and profiles were not affected by erythropoietin. Pharmacokinetics of erythropoietin suggest that the dose given was possibly too low to exert neuroprotection. (Source: Critical Care Medicine)
Source: Critical Care Medicine - March 15, 2018 Category: Emergency Medicine Tags: Clinical Investigations Source Type: research
A novel outpatient desensitization protocol for recombinant human erythropoietin allergy in a pediatric patient
Recombinant human erythropoietin, such as epoetin alfa and darbepoetin alfa, is an important therapy for anemia due to chronic renal failure. Allergy to recombinant human erythropoietin and the need for desens... (Source: Allergy, Asthma and Clinical Immunology)
Source: Allergy, Asthma and Clinical Immunology - March 12, 2018 Category: Allergy & Immunology Authors: Jaime S. Rosa, Van B. Vuong, Orly Haskin and Anne Y. Liu Tags: Case report Source Type: research
